Paid Clinical Trials Buffalo
Discover 651 paid clinical trials in Buffalo. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
Sponsor:
Cyclacel Pharmaceuticals, Inc.
Location:
Code:
NCT01211457
Conditions
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
sapacitabine and decitabine (Part 1 - completed)
sapacitabine and venetoclax (Part 2 - recruiting)
An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
Sponsor:
XenoPort, Inc.
Location:
Code:
NCT02560766
Conditions
RLS
Eligibility Criteria
Sex: All
Age: 13 - 17
Healthy Volunteers: Not accepted
Interventions
HORIZANT 300 mg
HORIZANT 600 mg
Placebo
Reparixin in Patients with Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Sponsor:
Icahn School of Medicine at Mount Sinai
Location:
Code:
NCT05835466
Conditions
Myelofibrosis (PMF)
Post Essential Thrombocythemia Myelofibrosis (ET-MF)
Post Polycythemia Vera Related Myelofibrosis (PV-MF)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
reparixin
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Sponsor:
Target PharmaSolutions, Inc.
Location:
Code:
NCT03661866
Conditions
Atopic Dermatitis
Alopecia Areata
Hidradenitis Suppurativa
Vitiligo
Psoriasis
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Sponsor:
AstraZeneca
Location:
Code:
NCT06283966
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Not accepted
Interventions
BGF MDI 320/14.4/9.6 μg
GFF MDI 14.4/9.6 μg
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Sponsor:
Bristol-Myers Squibb
Location:
Code:
NCT06003426
Conditions
Idiopathic Pulmonary Fibrosis
Eligibility Criteria
Sex: All
Age: 40+
Healthy Volunteers: Not accepted
Interventions
BMS-986278
BMS-986278 Placebo
A Trial Comparing Unrelated Donor BMT with IST for Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT, BMT CTN 2202)
Sponsor:
Boston Children's Hospital
Location:
Code:
NCT05600426
Conditions
Severe Aplastic Anemia
Eligibility Criteria
Sex: All
Age: 0 - 25
Healthy Volunteers: Not accepted
Interventions
cyclosporine
Matched Unrelated Donor Hematopoetic Stem Cell Transplant
horse anti-thymocyte globulin (ATG)
rabbit anti-thymocyte globulin (ATG)
Methotrexate
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
Sponsor:
Arog Pharmaceuticals, Inc.
Location:
Code:
NCT03258931
Conditions
Newly Diagnosed FLT3 Mutated AML
Eligibility Criteria
Sex: All
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Crenolanib
Midostaurin
Cytarabine
Duanorubicin
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
Sponsor:
AstraZeneca
Location:
Code:
NCT06268873
Conditions
Chronic Kidney Disease and Hypertension
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Baxdrostat/dapagliflozin
Dapagliflozin in combination with placebo